ierdenervatie als behandeling van hoge bloeddruk na niertransplantatie.
- Conditions
- therapy resistant hypertension, kidney allograft recipients.(therapie resistente hypertensie, niertransplantatiepatienten)
- Registration Number
- NL-OMON23051
- Lead Sponsor
- Academic Medical Center (AMC)
- Brief Summary
n/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1. Renal graft in situ since > 6 months, measured creatinine clearance >35 ml/min and;
2. A diuresis > 200ml/day of the native kidneys at time of transplantation or radiological evidence of residual flow in the renal arteries indicating that they are accessible for the intervention and;
Exclusion Criteria
1. (Planned) pregnancy, lactation;
2. Life expectancy < 1 year;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in daytime ambulatory blood pressure after 6 months.
- Secondary Outcome Measures
Name Time Method 1. Change in measured creatinine clearance after 6 months;<br /><br>2. Change in eGFR after 6 months.<br><br /><br /><br>Efficacy aspects: <br /><br>1. Change in 123I-metaiodobenzylguanidine (123I-MIBG) uptake of native kidneys;<br /><br>2. Change in systemic sympathetic activity and plasma rennin and aldosterone activity;<br /><br>3. Change in number of antihypertensive drugs after 6 months;<br /><br>4. Change in health related quality of life after six months;<br /><br>5. Change in compliance to the use of anti-hypertensive medications after 6 months;<br /><br>6. Change in proteinuria after 6 months.